VRAX
Virax Biolabs Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$2.63
+2.54%Year over year
Reported trailing growth
- Revenue
- -87.7%
- EBITDA
- —
- EBIT
- -23.9%
- EPS
- +24.5%
- Free cash flow
- -11.4%
- Operating cash flow
- -16.1%
Forward estimates
Based on analyst estimates
- Revenue
- -31.8%
- EBITDA
- +97.7%
- EPS
- +97.4%
Three-year CAGR
- Revenue
- +13.2%
- EBITDA
- +6.4%
- EBIT
- -3.8%
- Net income
- +17.1%
- EPS
- +74.2%
- Free cash flow
- +5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026